WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
SoftBank-backed PayPay (PAYP.US) IPO priced at $16, below the previously recommended range.
US Stock Market Move | Encrypting mining companies have increased their gains, IREN (IREN.US) up nearly 7%
Evening hot topic in A-shares | The People's Bank of China speaks out! Actively and prudently, safely and orderly promoting the application of artificial intelligence in the financial field.
SoftBank-backed PayPay (PAYP.US) IPO priced at $16, below the previously recommended range.
US Stock Market Move | Encrypting mining companies have increased their gains, IREN (IREN.US) up nearly 7%
Evening hot topic in A-shares | The People's Bank of China speaks out! Actively and prudently, safely and orderly promoting the application of artificial intelligence in the financial field.
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026
